Article
Elimusertib (BAY1895344), a novel ATR inhibitor, demonstrates in vivo activity in ATRX mutated models of uterine leiomyosarcoma.
Gynecologic oncology - 1 Jan 2023
Harold Justin, Bellone Stefania, Manavella Diego D, Mutlu Levent, McNamara Blair, Hartwich Tobias Max Philipp, Zipponi Margherita, Yang-Hartwich Yang, Demirkiran Cem, Verzosa Miguel Skyler, Choi Jungmin, Dong Weilai, Buza Natalia, Hui Pei, Altwerger Gary, Huang Gloria S, Andikyan Vaagn, Clark Mitchell, Ratner Elena, Azodi Masoud, Schwartz Peter E, Santin Alessandro D
Abstract excerpt
INTRODUCTION: Uterine leiomyosarcoma (uLMS) is a rare, highly aggressive malignancy. Recent data suggest 50% of uLMS may harbor alterations in the ATRX gene and such mutations may confer sensitivity to ataxia-telangiectasia-and-Rad3-related (ATR) kinase inhibitors. We sought to investigate the in vivo activity of Elimusertib (BAY1895344), a novel ATR-inhibitor, against ATRX-mutated uLMS patient-derived xenografts...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.